Professor Ewan Pearson
Clinical Professor (Teaching and Research)
Population Health and Genomics, School of Medicine
+44 (0)1382 383387
Ewan Pearson is Professor of Diabetic Medicine at the University of Dundee, Visiting Professor at the University of Edinburgh, and Honorary Consultant in Diabetes and Endocrinology at Ninewells Hospital and Medical School in Dundee. In the School of Medicine, he is the Head of Division, Population Health & Genomics, and the Director of the Dundee Clinical Academic Track.
Professor Pearson obtained his medical degree from the University of Cambridge School of Clinical Medicine, UK. He undertook a Wellcome Trust Clinical Training fellowship with Prof Andrew Hattersley at the University of Exeter Medical School, UK and completed his PhD in the physiology and treatment of monogenic diabetes. He then moved to Dundee where he was supported by a Chief Scientist Office Clinician Scientisit fellowship and, more recently, by a Wellcome Trust Investigator Award. Over the last ten years in Dundee his research interests have been in the phenotypic and genotypic determinants of drug response in diabetes, and in stratified approaches to the management of diabetes. He leads the IMI-DIRECT project on stratification in type 2 diabetes and is strand 2 lead on the ABPI-MRC funded MASTERMIND project. Ewan has been awarded the Royal College of Physicians of Edinburgh Croom Lecture, an EASD Rising Star award, the Diabetes UK RD Lawrence Lecture and the EASD Minkowski Award for his work in these areas.
The effectiveness of some common type 2 diabetes medications may depend upon an individual’s genetic make-up, a University of Dundee study has found.
A major new study is allowing people living with type 2 diabetes to choose their medication.
A University of Dundee expert will help spearhead a major research initiative to untangle the link between diabetes and heart disease - two of the biggest health crises in Scotland.
Professor Pearson is a clinical academic diabetologist whose research includes discovery and implementation of precision medicine approaches to the management of diabetes and obesity, and pharmacogenetics of commonly used drugs. Areas of expertise include monogenic diabetes, human physiology, precision medicine trials, population genomics and pharmacogenomics.
I am available for media commentary on my research.
Contact Corporate Communications for media enquiries.
Areas of Expertise